Dan Karelitz is a partner in the firm's Business Law Department and a member of the Tax group. Mr. Karelitz has strong general tax experience, advising sponsors on fund formation and portfolio company acquisition, disposition, and restructuring matters in the technology, private equity and real estate spaces. In addition, borrowing on deep experience in the private equity and real estate transaction space, and combined with his background as an organic chemist, Mr. Karelitz has a particular focus on the Life Sciences sector advising clients on structuring their operations, strategic transactions, acquisitions and divestitures in a tax-efficient manner.

He joined Goodwin in 2007.

Areas of Practice
Domaines D’Expertise





Representative Matters



Public Offerings
  • Orchard Therapeutics in its $225 million initial public offering
  • AquaVenture Holdings in its $117 million initial public offering
  • Intellia Therapeutics in its $108 million initial public offering
  • CRISPR Therapeutics in its $56 million initial public offering and its $200 million follow-on offering
Private Financings
  • Moderna Therapeutics in its $110 million Series D financing and $500 million Series E financing
  • Intellia Therapeutics in its $15 million Series A financing and $70 million Series B financing
  • Nimbus Therapeutics in its $43 million Series B financing and $65 million Series C financing
  • Scholar Rock in its $36 million Series B financing and $47 million Series C financing
  • Cullinan Oncology in its $150 million Series A financing
  • Kymera Therapeutics in its $30 million Series A financing
  • Ginkgo Bioworks in its agreement with Bayer to launch JoynBio for $100 million Series A investment
Strategic Collaborations and M&A
  • Teva Pharmaceuticals in its $3.2 billion acquisition of Auspex Pharmaceuticals
  • Versant Ventures in its strategic transaction with Bayer to form BlueRock Therapeutics, with a combined financing amount of $225 million
  • Foundation Medicine in its strategic collaboration with Roche, valued at more than $1 billion, and subsequent $2.2 billion merger with Roche
  • Quartet Medicine in its $595 million strategic collaboration with Merck
  • Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead, with $400 million upfront and the potential to receive an additional $800 million over time and strategic alliance with Celgene Corporation in immunology
  • CRISPR Therapeutics in its collaboration with Bayer, valued up to $335 million upfront
  • Padlock Therapeutics in its $225 million sale to Bristol Myers Squibb
  • F-star Alpha in its agreement with Bristol-Myers Squibb
  • Moderna Therapeutics in its collaboration with AstraZeneca to co-develop and co-commercialize immune-oncology mRNA Therapeutics 
  • Warp Drive Bio in its acquisition by Revolution Medicines
  • Sage Therapeutics in its collaboration with Shionogi for $90 million up front and potential deal value in excess of $575 million
  • Pairwise Plants in its collaboration with Monsanto to advance agriculture research and development by leveraging gene editing technology for $100 million
  • Alnylam Pharmaceuticals on its strategic restructuring of its RNAi therapeutics alliance with Sanofi

In The News









J.D., 2008
Georgetown University

(magna cum laude, Order of the Coif)

M.S., 2004
Emory University
B.S., 2004
Emory University

(Phi Beta Kappa)



Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique